Novel concepts in androgen receptor blockade

Andrew C. Hsieh, Charles J. Ryan

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Androgen receptor blockade is a cornerstone of treatment for prostate cancer. Despite castrate levels of testosterone, activation of the androgen receptor remains an important mediator of disease progression in the androgen "independentg" state. Thus, maximal blockade of androgen receptor signaling is a continual goal in the management of castration-resistant prostate cancer. In this review we will discuss how various aspects of androgen receptor signaling are being targeted for therapeutic development in castration-resistant prostate cancer. These include direct androgen receptor inhibitors, inhibitors of adrenal androgen synthesis, and a dual 5α-reductase isoenzyme inhibitor.

Original languageEnglish (US)
Pages (from-to)11-14
Number of pages4
JournalCancer Journal
Issue number1
StatePublished - Jan 1 2008
Externally publishedYes


  • Abiraterone
  • Androgen receptor
  • BMS-641988
  • Dutasteride
  • Ketoconazole
  • MDV3100


Dive into the research topics of 'Novel concepts in androgen receptor blockade'. Together they form a unique fingerprint.

Cite this